Evaluation of adenovirus capsid labeling versus transgene expression.
Adenoviral vectors have been utilized for a variety of gene therapy applications. Our group has incorporated bioluminescent, fluorographic reporters, and/or suicide genes within the adenovirus genome for analytical and/or therapeutic purposes. These molecules have also been incorporated as capsid components. Recognizing that incorporations at either locale yield potential advantages and disadvantages, our report evaluates the benefits of transgene incorporation versus capsid incorporation. To this end, we have genetically incorporated firefly luciferase within the early region 3 or at minor capsid protein IX and compared vector functionality by means of reporter readout.
Li
Jing
J
Division of Human Gene Therapy, Department of Medicine, Gene Therapy Center, University of Alabama at Birmingham, AL 35294, USA.
Fatima
Aiman
A
Komarova
Svetlana
S
Ugai
Hideyo
H
Uprety
Priyanka
P
Roth
Justin C
JC
Wang
Minghui
M
Oster
Robert A
RA
Curiel
David T
DT
Matthews
Qiana L
QL
D000256:Adenoviridae / Q000235:genetics* / Q000502:physiology; D036022:Capsid Proteins / Q000235:genetics* / Q000378:metabolism; D017930:Genes, Reporter; D006801:Humans; D008156:Luciferases / Q000235:genetics / Q000378:metabolism; D008967:Molecular Biology / Q000379:methods*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D013194:Staining and Labeling / Q000379:methods; D019076:Transgenes; D014773:Virology / Q000379:methods*
D036022:Capsid Proteins; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D008156:Luciferases